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Pathophysiilogy of the coronary circulation is a 
major contributor to altering the myocardial sub- 
strate, rendering the heart susceptible to the on- 
set of arrhythmias asso&ted with sudden car- 
dii death. Antiirrhythmic drug therapy for the 
prevention of sudden card& death has been pro- 
vided primarily on the bask of trial and error and 
in some instances based on ill-suited preclinkal 
evaluations. The findings of the Cardiac Arrhyth- 
mia Suppression Trial (CAST) requires a reexami- 
nation of the manner in which antiirrhythmk 
drugs are developed before entering into clinkal 
testing. The major defkiency In thii area of ex- 
perimental imrestigation has been the lack of ani- 
mal models that would permit preclinkal studies 
to identify potentiilly useful or deleterious thera- 
peutk agents. Further, CAST has emphasized the 
need to distinguish between pharmacologk inter- 
ventiins that suppresses nonlethal distutinces 
of cardiac rhythm as opposed to those agents 
capable of preventing lethal ventrkular tachycar- 
dia or ventrkular fibrillatko. Preclinical models 
for the testing of antifibrillatory agents must 
consider the fact that the superimpositkn of 
transient ischemii events on an underlying 
pathophysiologk substrate makes the heart sus- 
ceptible to lethal arrhythmias. Proarrhythmk 
events, not observed in the normal heart, may 
become manifest only when the myocardiil sub- 
strate has been attered. We describe a model of 
sudden cardiac death that may more ctosely 
simulate the clinkal state in humans who are at 
risk. The experhnental results show a good corre- 
lation with clinical data regarding agents known 
to reduce the hwidence of lethal arrhythmias as 
well as those showing proarrhythmk actions. 
(Am J Cardiol l99~72:2JF--44F) 
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A major cause of mortality in the United States as well as in other parts of the industrialized world is attributed to sud- 
den cardiac death, a phenomenon most likely to 
occur in the diseased heart as a result of altered 
electrophysiology. “Sudden cardiac death” gener- 
ally denotes death that is nonviolent, unexpected, 
witnessed, and instantaneous or occurs within a 
few minutes of an abrupt change in the previous 
clinical state.’ Despite a decrease in the number of 
sudden cardiac deaths over the past 20 years, the 
number of fatalities in the United States exceeds 
300,000 per year. Approximately 60% of the fatal 
events occur in individuals without any previous 
diagnosis of heart disease.2 Clearly, sudden cardiac 
death is a major health issue of our times, account- 
ing for 50% of all cardiovascular deaths,3 and the 
problem is compounded by the recent realization 
that not only has pharmacologic management done 
little to improve the situation, it may have contrib- 
uted to the onset of the fatal events in susceptible 
individuals.4 The extent of the problem has made 
sudden cardiac death one of the most pressing 
unresolved clinical and public health concerns. 
In most instances of sudden cardiac death, the 
underlying pathophysiology of the coronary artery 
circulation renders the heart susceptible to the 
onset and maintenance of a lethal dysrhythmia. 
That the “triggering” event is of a transient nature 
is suggested by the fact that patients resuscitated 
after sudden coronary death are capable of main- 
taining a stable cardiac rhythm and, in many 
instances, do not display signs and symptoms sug- 
gestive of permanent myocardial injury. It is of 
fundamental importance, therefore, to understand 
what possible electrophysiologic factor (or factors) 
results in the transition from a stable activation 
sequence of the ventricular myocardium to one 
with multiple asynchronous circuits culminating in 
ventricular fibrillation. It is equally important to 
know what morphologic and electrophysiologic 
changes characterize the portion of the myocar- 
dium that is capable of serving as a suitable sub- 
strate for the triggering event that proceeds to 
ventricular fibrillation. 
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The ischemically injured heart shows marked 
heterogeneity with respect to regional coronary 
artery blood flow to areas subserved by stenosed 
vessels. Further, ion fluxes, availability of sub- 
strate, and the superimposition of neural influ- 
ences are capable of exerting deleterious effects, 
which render the heart more susceptible to the 
triggering event leading to the onset of ventricular 
fibrillation. 
Sudden cardiac death may be considered to 
involve an interaction between structural derange- 
ments of the heart, transient functional distur- 
bances, and the specific electrophysiologic events 
responsible for the fatal arrhythmia.3 Coronary 
atherosclerosis and its associated influences on the 
heart constitutes the major pathologic finding in 
the vast majority of persons who succumb to 
sudden cardiac death. Patients who have experi- 
enced a major cardiovascular event are at high risk 
of sudden cardiac death during the first 6-18 
months after the index event, suggesting a time 
dependence of risk and indicating the need for 
appropriate therapy in the early period.5 
THE PRERBRlUATORY STATE 
understaltding the factors that characterize 
the prefMllatory state as targets for drug 
intervention: The role of drug intervention in the 
prevention of sudden death is based on the premise 
of there being treatable factors that can be identi- 
fied in those at risk. One factor, recognized for 
many years, is the finding of chronic ventricular 
ectopy in patients after myocardial infarction.6-11 
The assumption was made that premature ventricu- 
lar complexes appearing in the vulnerable phase of 
myocardial repolarization were responsible for the 
initiation of malignant arrhythmias in these indi- 
viduals. Therefore, it seemed entirely appropriate 
that an agent capable of suppressing premature 
ventricular complexes would be effective in prevent- 
ing sudden death. Indeed, early studies with lido- 
Caine, an effective agent in suppressing ectopy,12 
suggested that its use might be associated with a 
decreased incidence of ventricular fibrillation.13 
After this, however, there appeared a number of 
reports using several agents that failed to substanti- 
ate this claim and, when reviewed in early meta- 
analysis, appeared to suggest an adverse trend.14J5 
Nevertheless, the analyses were not without criti- 
cism for dissimilarities in study designs and popula- 
tions, so it was not until the advent of the Cardiac 
Arrhythmia Suppression Trial (CAST) that the 
prescribing public was given a clear picture of the 
issue. CAST was designed specifically to address 
the question of whether premature ventricular 
complex suppression was an appropriate surrogate 
for mortality in the postmyocardial infarction popu- 
lation. Encainide, flecainide, and moricizine were 
identified in the Cardiac Arrhythmia Pilot Study 
(CAPS)16 as “premature ventricular complex 
killers” and were considered to be the agents of 
choice for CAST. Despite (ironical) concern over 
the ethics of a placebo arm, it was included in the 
major multicenter study, which employed an el- 
egant dose titration in a double-blind manner. 
Preliminary (CAST I) and final (CAST II) results 
from this study provided the definitive answer that 
the use of all 3 agents was associated with signifi- 
cant increases in arrhythmic deaths.17J8 Further, 
the adverse trends were apparent in all identified 
subgroups and, in view of the diverging curves, 
were thought to be ongoing throughout the trial. 
An alternative clinical model for the testing of 
antiarrhythmic drugs is the unmasking of malig- 
nant reentrant arrhythmias by electrophysiologic 
testing. An appropriately timed stimulus, delivered 
through an in-dwelling cardiac catheter, can in- 
duce ventricular tachyarrhythmias in patients at 
risk of life-threatening disturbances in cardiac 
rhythm.19 Further, the same arrhythmias may be 
prevented by the use of individualized drug 
therapy.*OJl The induction of sustained ventricular 
arrhythmia is considered an objective endpoint by 
which to evaluate candidates for antiarrhythmic 
drug therapy. The rate at which inducible ventricu- 
lar arrhythmias are suppressed during serial antiar- 
rhythmic drug testing in survivors of sudden car- 
diac death is in the range of 20-50%.20~22~23 However, 
even when ventricular fibrillation is induced by 
programmed electrical stimulation in the electro- 
physiology laboratory, one cannot be sure that the 
substrate of the arrhythmia thus generated is 
identical to that pertaining at the time of sudden 
death, or that pharmacologic prevention of stimu- 
lus-induced ventricular fibrillation reflects protec- 
tion against sudden death. The question remains, 
therefore, whether it is the fact that a patient’s 
arrhythmia can be suppressed that is important, or 
if it is due to the associated drug therapy; in other 
words, is suppressibility per se associated with a 
good prognosis? To answer this would require a 
placebo-controlled trial in which patients with 
suppressible arrhythmias were compared with pa- 
tients whose arrhythmias could not be prevented, 
but before embarking on this we must first be 
assured that electrophysiologic testing is an appro- 
priate surrogate for mortality. The only study to 
date that addresses this question is the National 
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Institutes of Health-sponsored Electrophysiology 
Study Versus Electrocardiographic Monitoring 
(ESVEM) tria1.24 ESVEM uses mortality in deter- 
mining the relative usefulness of electrophysiologic 
testing and Holter monitoring in assessing several 
antiarrhythmic agents, including quinidine, procain- 
amide, mexiletine, propafenone, sotalol, and pirme- 
no1 (a class IA agent no longer being developed). 
An imipramine group was removed shortly after 
the trial was initiated. Until this trial reports in 
1993, electrophysiologic testing cannot be recom- 
mended for routine use. 
To summarize the clinical situation, therefore, 
whereas certain drugs (e.g., lidocaine, bretylium, 
amiodarone, and most recently, sotalol) do have 
the indication for prevention of recurrent ventricu- 
lar fibrillation, no pharmacologic intervention has 
yet been shown to decrease the incidence of 
sudden cardiac death. Further, there appears to be 
no relevant surrogate endpoint for the evaluation 
of potential new therapies. The results of CAST 
have demonstrated that clinical testing of antiar- 
rhythmic drugs cannot rely on a drug’s ability to 
reduce the frequency and/or complexity of ventricu- 
lar premature depolarizations. Even the applica- 
tion of more elaborate procedures, such as electro- 
physiologic testing for the evaluation of a drug’s 
antiarrhythmic efficacy, may be misleading with 
respect to its efficacy in preventing the develop- 
ment of ventricular fibrillation. As long as the 
endpoint remains anything other than sudden car- 
diac death, any clinical trial or clinical use of a drug 
in patients determined to be at high risk will be 
carried out mostly on an empirical basis. An 
essential component in approaching the develop- 
ment of effective therapeutic interventions for the 
prevention of sudden cardiac death must include 
appropriate animal models for early preclinical 
testing, based on an understanding of the patho- 
physiologic milieu pertaining at the time of sudden 
death. At present, the approach to identifying 
therapeutic interventions for prevention of lethal 
arrhythmias is predicated on a drug’s ability to 
alter various characteristics of the membrane ac- 
tion potential of cardiac tissues, alterations in ion 
channel function, or examination of the drug’s 
ability to prevent or terminate one or more experi- 
mentally induced dysrhythmias. Unfortunately, few 
of the experimental approaches have a close rela- 
tion to several important questions: First, can the 
agent under study prevent ventricular fibrillation? 
Second, can it serve as a candidate drug for a highly 
focused clinical trial in well-characterized subsets 
of patients who possess identifiable specific etio- 
logic features placing them at risk of succumbing to 
sudden cardiac death? Lastly, does the therapeutic 
agent of interest confer an antifibrillatory action 
under conditions in which the altered substrate 
(damaged myocardium) is subjected to transient 
ischemic events? The latter is of primary impor- 
tance, since a drug capable of preventing or sup- 
pressing spontaneous or electrophysiologically in- 
duced reentrant rhythms in the nonischemic 
myocardium may be proarrhythmic or profibrilla- 
tory under conditions in which transient ischemic 
episodes are superimposed on a vulnerable sub- 
strate. 
THE MYOCARDIAL SUBSTRATE 
Theessentiilsubstrateforreemtrantrhythms 
and ventricular fibrillatton: Postmortem studies 
indicate that in the majority of cases, ventricular 
fibrillation is a primary event and not related to 
acute myocardial infarction.25,26 Sudden cardiac 
death is known to occur most commonly in patients 
with previous myocardial ischemic injury second- 
ary to advanced coronary artery atherosclero- 
sis.27-29 Further, the finding in many cases of 
intracoronary thrombus without acute infarction 
suggests that ischemia, per se, may be acting as the 
trigger for the genesis of ventricular fibrillation in a 
vulnerable, electrically unstable ventricular myocar- 
dium. The electrophysiologic properties of isch- 
emit myocardium, such as increased excitability, 
shortening of the ventricular refractory period, 
slowing of conduction velocity, and increased inho- 
mogeneity in recovery may provide the milieu for 
the emergence of reentrant rhythms in a heart 
critically deranged by previous infarction. The 
concept of ischemia in a region remote from the 
infarct-related artery acting as the trigger for fatal 
ventricular arrhythmias was addressed by Schuster 
and Bulkley.30 In a study of 2 groups of patients 
with early postinfarction angina, they found that 
patients with remote ischemia constituted a group 
of hemodynamically stable patients who faced an 
unexpectedly high mortality compared with those 
patients whose angina arose from the peri-in- 
farcted region. Schwartz and coworkers31,32 repro- 
duced this phenomenon experimentally when they 
demonstrated a high incidence of ventricular fibril- 
lation in a chronic canine model of myocardial 
infarction in which additional ischemia was initi- 
ated using a hydraulic coronary artery occluder. 
Also using a canine model, Kabell and coworkers3” 
demonstrated a diminution in infarct collateral 
blood flow with distant ischemia. Since this was 
preceded by delayed epicardial activity within the 
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area of preexisting infarction, it suggested that 
&hernia might be influencing the substrate of an 
infarcted area of myocardium to render it more 
suitable for the emergence of lethal arrhythmias. 
Coronary vasospasm has been considered as a 
triggering mechanism for sudden death, especially 
since patients with atypical angina have demon- 
strated serious ventricular arrhythmias during epi- 
sodes of spasm. 34 Although the majority of survi- 
vors of cardiac arrest give no previous or subsequent 
history of atypical angina, in one study sudden 
death was observed in 17% of 114 patients with 
coronary vasospasm followed for a mean of 24 
months.35 
The concept that spasm may be an important 
contributor to sudden cardiac death is supported 
by data showing the relation between the disease- 
free wall of the coronary artery and the severity of 
obstruction.3627 The mean disease-free wall arc 
length measured 17-23% of the total vessel circum- 
ference in eccentric coronary lesions that ob- 
structed 50-90% of the cross-sectional area of the 
lumen. The ratio persisted regardless of the loca- 
tion of the lesion within the vessel. The normal arc 
may be capable of responding to vasospastic stimuli, 
as opposed to atheromatous material occupying 
the bulk of the arc, which appears firm and unlikely 
to change configuration in response to humoral or 
neurogenic stimuli. The potential exists for the 
dynamic alterations in coronary luminal dimen- 
sions most likely to occur along the disease-free 
circumference of the coronary artery. Thus, a 
clinically silent atherosclerotic lesion could be 
converted to a clinically symptomatic and possibly 
lethal lesion by additional spasm in the plaque-free 
segment of the vessel. Postmortem examination of 
human coronary artery segments has led to the 
suggestion that the atherosclerotic process leads to 
a decrease in density or sensitivity of the p adreno- 
ceptors in the smooth muscle of the coronary 
arteries.38 The conclusion was that the intrinsic 
properties of human coronary smooth muscle may 
be one of the mechanisms of coronary spasm. 
There are no unequivocal markers at the time of 
necropsy to demonstrate that coronary artery spasm 
preceded the fatal arrhythmia. However, a distinc- 
tive finding in smooth muscle of coronary arteries 
suggestive of antemortem spasm has been reported 
in which “hypercontraction” of smooth muscle 
cells may give rise to dense eosinophilic bands, 
similar to those seen in reperfused cardiac muscle.39 
Coronary artery contraction bands were found in 
75% of the cases examined and were more com- 
mon in vessels with <50% cross-sectional area 
obstruction than vessels with > 50% obstruction. 
Another mechanism to be considered in the 
genesis of lethal arrhythmias is the role of the 
autonomic nervous system. Alterations in auto- 
nomic tone are well recognized in acute myocardial 
ischemia and may be inherently arrhythmogenic by 
nature of the increase in myocardial oxygen con- 
sumption and alterations in refractoriness. Inho- 
mogenous adrenergic stimulation has been shown 
to precipitate arrhythmias in a number of animal 
models,40 whereas others have demonstrated a 
possible role of the sympathetic nervous system 
when acute ischemia is produced in the setting of 
previous myocardial infarction.31,32z41 Specifically, 
sympathetic hyperactivity favors the onset of life- 
threatening cardiac arrhythmias, whereas vagal 
activation exerts a protective and antifibrillatory 
effect.41 Direct neural recording of vagal activity to 
the heart confirmed that vigorous reflex vagal 
activation during acute myocardial ischemia is 
associated with protection from ventricular fibrilla- 
tion.42 Other factors contributing to the precipitat- 
ing trigger in sudden death include those biochemi- 
cal alterations (such as hypokalemia and 
hypomagnesemia) that are known to precipitate 
fatal arrhythmias in individuals at risk. Thus, a 
variety of factors may predispose the individual at 
risk to the development of lethal ventricular ar- 
rhythmias (Figure 1). Pathophysiologically, sudden 
cardiac death involves an interaction between struc- 
tural abnormalities of the heart, transient func- 
tional disturbances, and the specific electrophysi- 
ologic events responsible for fatal arrhythmias. 
ISCHEMIA MUST BE DIFFERENTIATED 
FROM INFARCTlON 
There is a period of healing after myocardial 
infarction in which the necrotic mass of tissue is 
converted to a dense, fibrous scar. The healed 
phase of myocardial infarction is characterized by a 
chronic alteration in myocardial structure that, in 
itself, is electrically stable. However, the structural 
abnormality is capable of influencing electrophysi- 
ologic parameters when other events are superim- 
posed on the heart. In contrast, ischemia is a 
transient event due to an absolute or relative 
reduction in regional myocardial blood flow. The 
influence of ischemia on a structurally normal 
heart has a more favorable outcome compared 
with an ischemic event superimposed on a heart 
previously subjected to myocardial infarction. There 
is compelling evidence to indicate that regional 
myocardial ischemia superimposed on the previ- 
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ously damaged heart, in contrast to a normal heart, 
is more likely to precipitate malignant and poten- 
tially lethal ventricular arrhythmia.4345 Superimpo- 
sition of an acute nonocclusive thrombus, an imbal- 
ance between oxygen supply and demand, metabolic 
or electrolyte changes, or neurophysiologic influ- 
ences may establish the conditions necessary to 
sustain a reentrant rhythm leading to a lethal 
arrhythmia. Enhanced coronary artery vasomotor 
activity abruptly decreasing myocardial blood flow 
in a region remote from a region of previous 
myocardial infarction may precipitate symptoms of 
angina, disturbances in rhythm, and sudden car- 
diac death.35,46 Platelet aggregation at sites of 
coronary vessel damage and the release of vasoac- 
tive mediators have been implicated as major 
contributors to the initiation of lethal cardiac 
arrhythmias.47-50 
PRECUNICAL ASSESSMENT 
Antifibrlllatory drug efficacy, using relevant 
experimental models: It is not our intent to 
discuss the pros and cons concerning the multitude 
of experimental models used for the study of 
antiarrhythmic drugs. Table I presents a listing of 
some of the more commonly used experimental 
models. The subject has been reviewed in detail in 
previous publications. 51-54 Whole animal models 
for the evaluation of antiarrhythmic activity have 
relied on arrhythmias induced by cardiotoxic agents, 
electrical stimuli, or arrhythmias associated with 
coronary artery occlusion, with or without reperfu- 
sion.53 Other approaches include arrhythmias in- 
duced by catecholamines55 or electrical stimuli56,57 
in the subacute phase of myocardial infarction. 
Although each of these techniques is capable of 
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TABLE I Methods for Preclinical Evaluation of Antiarrhythmic 
Agents 





Potassium channel openers 
Electrically Induced arrhythmias 
Ventricular fibnllation/defibrillatron threshold 
Repetitive ventricular response 
Programmed electrrcal stimulation 
Neurally induced arrhythmias 
Application of strmuli to the lateral ventricle of the brain 
Electrrcal stimulation of the autonomic nervous system 
Emotional- or exercise-Induced stress 
lschemia induced arrhythmias 
Acute interruption of regional coronary artery blood flow (Harris 1 or 2 
stage) 
Acute interruption of regional coronary artery blood flow followed by 
reperfusion 
Acute regronal ischemia superimposed on a previously infarcted myo- 
cardium 
r 
generating reliable and reproducible arrhythmias, 
they fail to provide an opportunity to examine the 
electrophysiologic environment at the time of ven- 
tricular fibrillation, or to study pharmacologic inter- 
ventions aimed at preventing sudden cardiac death. 
The preclinical development of antiarrhythmic 
agents should emphasize the importance of design- 
ing animal models to address ventricular fibrilla- 
tion, since it may represent one of the primary 
rhythm disturbances associated with sudden car- 
diac death, particularly in the heart altered by the 
presence of coronary artery disease. In light of the 
CAST results,17 animal models that evaluate a 
drug’s capacity to reduce the number of innocent 
SUPERIMPOSED INSULTS 
TRANSIENT MYOCARDIAL ISCHEMIA 
Platelet Aggregates 
Serotonin, Thromboxane, ADP 
Increased Coronary Artery Tone/Spasm 
Endothelial Cell Dysfunction 
Altered Autonomic Nervous System Activity 
Neurotransmitter Release, Receptors 
Altered Regional Myocardial Blood Flow 
Central Nervous System Influences 















Premature Ventricular Complexes 
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TABLE II Characteristics of the Chronic Canine Model of 
Sudden Death 
Features lndwble Noninducible 
Anterior infarct size 24.7 + 1.7 5.3 2 1.1* 
(% left ventricular mass) 
Time to lschemia (min) 196 + 39 225 + 30 
Sudden VF (< 1 hour) 11/15 2115 
Delayed VF ( < 24 hours) 3/15 O/15 
Thrombus mass (mg) 7.2 + 1.81 11.2 2 2.3 
Posterolateral Infarct mass 19.0 f 1.0 (n = 3) 16.7 2 2.3 (n = 13) 
*p <O.OOl. 
VF: Ventricularflbrillatlon. 
Summarized from Wllberet aL5* 
ventricular premature depolarizations may be of 
limited value in new drug development. The ideal 
drug may be one that is effective against sustained 
ventricular tachycardia/fibrillation that occurs 
“spontaneously” in the presence of previous myo- 
cardial injury. There may be a clear distinction 
between antiarrhythmic efficacy and antifibrilla- 
tory potential. It may not follow that the latter is 
simply an extension of the former. 
VENTRICULAR TACRYCARDlA AND SUDDEN 
CARDlAC DEATH 
An experimI model: Our group has made 
extensive use of a conscious canine model that is 
susceptible to the initiation of stimulus-induced 
ventricular arrhythmias in the subacute phase of 
anterior myocardial infarction.44T53 Of particular 
interest in this model was the finding that an 
additional ischemic insult (initiated by a 150 ~J,A 
anodal current to the left circumflex coronary 
artery) served as a reliable model for the spontane- 
ous onset of ventricular fibrillation. The study by 
Patterson et a144 also demonstrated that previous 
myocardial damage was a prerequisite for the 
observed high mortality, since dogs without ante- 
rior infarctions exhibited a low risk of ventricular 
fibrillation. A subsequent study58 evaluated the 
model further by looking at the relation between 
inducible ventricular tachycardia and the subse- 
quent development of ventricular fibrillation. Re- 
sults suggested that inducible arrhythmias (either 
sustained or nonsustained) were predictive of spon- 
taneous ventricular fibrillation during posterolat- 
era1 ischemia. The mass of previously injured 
myocardium was a critical determinant of both, 
since animals with inducible arrhythmias (24-hour 
mortality, 93%) had larger infarct sizes 
(24.7 + 1.7% of left ventricular mass) than the 
animals in which arrhythmias could not be induced 
at baseline testing (24-hour mortality, 15%; infarct 
size, 5.3 2 1.1% of left ventricular mass; Table II). 
Use of this canine model enabled evaluation of 
antiarrhythmic activity against arrhythmias thought 
to share the same reentrant basis as ischemic 
arrhythmias in humans. 56,59 In addition, the model 
permits discrimination between antiarrhythmic ac- 
tivity as determined with programmed electrical 
stimulation versus antifibrillatory activity in the 
postinfarcted heart subjected to an ischemic event 
in a region remote from the infarct-related artery. 
DETERMINING ANTlFlBRlU.ATORY ACTMlY 
Experhental procedure: Mongrel dogs of ei- 
ther sex are anesthetized by the intravenous admin- 
istration of sodium pentobarbital, intubated, and 
ventilated with room air. Using an aseptic tech- 
nique, the left jugular vein is isolated and cannu- 
lated for subsequent drug administration. A left 
thoracotomy is performed, and the heart exposed 
and suspended in a pericardial cradle. The left 
anterior descending (LAD) coronary artery is dis- 
sected free at the tip of the left atria1 appendage 
and the left circumflex (LCX) coronary artery 
isolated approximately 1 cm from its origin. Ante- 
rior wall infarction is achieved by a 2-hour occlu- 
sion of the LAD coronary artery followed by 
reperfusion in the presence of a critical stenosis. 
An epicardial bipolar electrode is sutured to the 
left atria1 appendage for subsequent atria1 pacing. 
A bipolar plunge electrode is sutured onto the 
surface of the heart in the region of the right 
ventricular outflow tract (RVOT) for the subse- 
quent introduction of extrastimuli during pro- 
grammed electrical stimulation. In addition, 2 
bipolar plunge electrodes are sutured to the left 
ventricular wall; 1 in the distribution of the LAD 
coronary artery distal to the site of occlusion 
(infarct zone) and the second in the distribution of 
the LCX coronary artery (normal zone). Finally, a 
30-gauge electrode is inserted into the lumen of the 
LCX coronary artery and secured by suturing to 
the heart wall. Figure 2 is a schematic representa- 
tion of the instrumented canine heart as used in 
the model of sudden cardiac death. 
Programmed electrical stimulation and electro- 
physiologic testing are performed in the conscious, 
unsedated animal, 3-5 days after surgical prepara- 
tion. After determination of the RVOT excitation 
threshold and refractory period, programmed 
stimulation continues with the introduction of 
double (S2, S3) and triple (S2, S3, S4) extrastimuli 
(4 msec duration at twice RVOT excitation thresh- 
old) during sinus rhythm. Previous studies indi- 
cated that these stimulation methods will not 
induce arrhythmias in sham-operated animals.44 
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Electrophysiologic parameters from normal and 
infarcted myocardium are determined from the 
construction of strength-interval curves using data 
obtained from the normal zone and infarct zone 
electrodes, respectively. Dogs with sustained or 
nonsustained ventricular tachycardia are allocated 
randomly to drug or vehicle groups, and electro- 
physiologic testing and programmed stimulation 
are repeated in full after drug equilibration. 
On completion of the post-treatment stimula- 
tion protocol, a direct anodal current of 150 ~J,A is 
applied to the intimal surface of the LCX coronary 
artery using a 9 V nickel-cadmium battery and 
variable resistor. Application of an anodal current 
to the intimal surface of the vessel results in injury 
and exposure of the underlying collagen matrix. 
Platelet aggregates form on the denuded surface of 
the coronary artery, accompanied by cyclic varia- 
tions in blood flow and a high incidence of acute 
ventricular fibrillation within 1 hour from the onset 
of ischemia as determined by depression or eleva- 
tion in the ST segment of the electrocardiogram. 
Lead II of the electrocardiogram is recorded at 
preset intervals (30 set every 15 min) by a program- 
mable cardiocassette recorder. After 24 hours of 
continuous application of the anodal current or the 
development of ventricular fibrillation, the heart is 
excised and any thrombus in the LCX coronary 
artery is removed and weighed. The heart is sec- 
tioned transversely and incubated in a 0.4% solu- 
tion of triphenyltetrazolium chloride for 15 min. 
Anterior and posterolateral areas of infarction are 
identified by their inability to reduce triphenyltetra- 
zolium chloride enzymatically to a brick-red forma- 
zan precipitate. Infarct masses in the myocardial 
regions are quantified by computer-assisted planim- 
etry and expressed as a percentage of total left 
ventricular mass. Playback of the cardiocassette 
provides information regarding the time of onset of 
ischemia (as assessed by the appearance of ventricu- 
lar ectopy and/or ST-segment changes), the time 
from ischemia to death, and the percent change in 
heart rate before death. When last tabulated, a 
total of 201 inducible, vehicle-treated dogs had 
been studied in our laboratory; of these, 188 (94%) 
had died within 24 hours of posterolateral ischemia 
in the sudden death protocol.60 
The results of various pharmacologic interven- 
tions in the conscious canine model of sudden 
death are summarized in Table III. The data in 
Table III illustrate the dichotomy of action of many 
antiarrhythmic agents when tested both against the 
arrhythmias of programmed electrical stimulation 
and in their effects against ischemic ventricular 
fibrillation. Based on these observations, it could 
be concluded that there is little, if any, value in 
predicting antifibrillatory efficacy from a drug’s 
effect on stimulus-induced ventricular tachycardia. 
It can be seen that clinically relevant plasma 
concentrations of the class IA agent quinidine were 
capable of preventing the induction of stimulus- 
induced arrhythmias, but were ineffective in pre- 
venting ventricular fibrillatiot#‘; conversely, if we 
ignore for the present the confounding issues with 
sotalol, B-adrenergic receptor blockade appears to 
be offering some degree of protection in the 
sudden death model without influencing stimulus- 
induced ventricular tachycardia,54%h2-64 a phenom- 
enon shared by the specific bradycardic agent 
alinidine.65 Studies with 2 calcium channel antago- 
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TA6l.E III Drug Efficacy in the Conscious Canine Model of 
Myocardial Infarction and Sudden Death 
Ventricular Tachycardia 
Suppression 24-Hour 
Agent (Programmed Stimulation) Survival (%) 
Vehicle - 6* 
Class I 
Quinidine + 9 
Flecainide - 14 
Class II 
Nadolol - 56-63 
Dilevalol - 20-60 
Sotalol + 63 
Celiprolol - 30 
Class III 
D-SOtalOl + 65 
Bretylium + 60 
Amiodarone - 40-80 
Clofilium + 30 
CK 3579t - 70 
Sematilide + 60 
E-4031 - 60 
UK 68,798 - 42 
Class IV 
Diltiazem - 10 
Bepridil + 30-40 
Other 
Alinidine - 60 
Meobentine - 0 
Bethanidme - 0 
Prazosin - 50 
CGS 12970$ - 30 
R 680709 - 30 
*Cumulatwe. 
tClass III with pi adrenoceptorantagonlst properties. 
tThromboxane synthetase (TS) inhibitor. 
$Combined TS inhibitor and receptor antagonist. 
Adapted from: Lynch and Lucchesl.54 
nists show bepridil to be antiarrhythmic without 
affecting mortality,@ whereas diltiazem did not 
demonstrate any beneficial effect.67 Studies with 
other agents not covered by the Vaughan Williams 
classification offer little additional insight into the 
antiarrhythmic or antifibrillatory relation.68-72 Even 
in the group with the greatest overall effect in the 
sudden death model, only half of the class III 
agents tested demonstrated a correlation with 
antiarrhythmic activity. Thus, it would seem reason- 
able to conclude that there is little prognostic value 
from suppression of ventricular tachycardia in this 
model, other than the ancillary electrophysiologic 
data obtained at the time of testing, which fre- 
quently provide an insight into potential antifibril- 
latory mechanisms. 
CONSCIOUS CANINE MODEL OF SUDDEN 
CARDIAC DEATH 
Clinical significance: A striking observation 
from Table III is the apparent lack of activity of the 
class I agents in preventing sudden death in the 
model. In light of what we have learned from 
CAST, the study with flecainide was particularly 
interesting in that 3 of 7 animals, noninducible at 
baseline and therefore at low risk from posterolat- 
era1 ischemia, failed to survive the sudden death 
protocol.73 Thus potential profibrillatory activity 
with flecainide had been suggested on the basis of 
preclinical studies several years before CAST. The 
class IC agents are characterized by their ability to 
slow conduction velocity with only minimal effects 
on the duration of the refractory period of the 
ventricular myocardium. Flecainide in particular is 
of interest in that it increases the ventricular 
effective refractory period and, to a lesser extent, 
the action potential duration. On the other hand, 
in Purkinje fibers, action potential duration is 
decreased as flecainide concentration increases.74 
In contrast to the actions of other antiarrhythmic 
agents that are sodium channel inhibitors, flecain- 
ide, like encainide, exerts a differential effect on 
repolarization in ventricular muscle and Purkinje 
fibers, an effect that is likely to aggravate heteroge- 
neity of excitability and refractoriness on the heart 
and may worsen ventricular tachyarrhythmias un- 
der certain experimental or clinical situations.74 
Depending on the length of the reentrant circuit, 
slowing of conduction velocity without a coincident 
lengthening of the refractory period may result in 
multiple reentrant circuits.75 Quinidine, as well as 
procainamide, 2 class IA antiarrhythmic agents, 
produce a prolongation of refractoriness and a 
rate-dependent depression of conduction velocity. 
The precise role of these electrophysiologic effects 
in mediating an antiarrhythmic action is not clear. 
Studies with procainamide76 indicate that lesser 
slowing of conduction velocity and greater prolon- 
gation of refractoriness tend to abolish reentry 
within the reentrant circuit. Drugs that prolong 
refractoriness appear more likely to be effective 
against tachycardia caused by reentry than are 
drugs that produce a slowing of conduction velocity 
as their major electrophysiologic effect.77 
The canine model of sudden cardiac death 
successfully identified the proarrhythmic action of 
flecainide. The antiarrhythmic and antifibrillatory 
effects of flecainide acetate during the early postin- 
farction period were evaluated in the conscious 
canine model of sudden cardiac death. Ventricular 
tachycardia remained inducible early after infarc- 
tion in 8 of 9 dogs receiving an intravenous loading 
dose of flecainide (2.0 mg/kg body weight) and 7 of 
8 dogs receiving saline vehicle. In both the drug 
and vehicle groups, there was no significant change 
in the ventricular refractory period or in the cycle 
length of the induced ventricular tachycardia. With 
a maintenance intravenous infusion of flecainide, 
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1.0 mg/kg/hr for 4 hours, the subsequent develop- 
ment of acute posterolateral ischemia resulted in 
ventricular fibrillation and sudden death in 7 of 8 
flecainide-treated and 8 of 8 vehicle-treated dogs. 
Seven additional postinfarction dogs with noninduc- 
ible tachycardia during pretreatment programmed 
stimulation, and thereby considered to be at low 
risk for the development of ischemic ventricular 
fibrillation,58 were given flecainide in an intrave- 
nous loading and maintenance dosing regimen. 
The subsequent occurrence of posterolateral isch- 
emia resulted in the development of ventricular 
fibrillation in 3 of these 7 dogs. The findings 
suggest that flecainide acetate may not possess 
pharmacologic properties useful in managing ven- 
tricular tachycardia or in preventing ischemic ven- 
tricular fibrillation in the presence of recent myo- 
cardial damage.73v78 
The only pharmacologic intervention shown to 
have a beneficial effect on sudden death is l3-adren- 
ergic receptor antagonism, where a number of 
studies in the postmyocardial infarction period 
have confirmed significant protection.79-83 In this 
context there also appears to be a good correlation 
with the conscious canine model of sudden death, 
since protection has been demonstrated with a 
number of agents. 54~63,64,84 The antiarrhythmic and 
antifibrillatory potential of p-adrenoceptor antago- 
nism, however, remains unclear; in particular, 
there is uncertainty over whether the drugs act by a 
direct antifibrillatory effect or via a primary antiisch- 
emit influence. This point is pursued in the follow- 
ing section. 
Although no individual study with a class III 
agent has yet demonstrated significant antifibrilla- 
tory activity, suggestions of a beneficial trend are 
apparent in a recent meta-analysis.85 The authors 
conducted an overview of randomized controlled 
trials of classes I and III antiarrhythmic agents and 
updated earlier overviews on classes II and IV 
antiarrhythmic drugs. A total of 137 trials involving 
96,000 patients made up the study population. It 
was concluded that mortality was increased signifi- 
cantly with class I antiarrhythmic agents, reduced 
with classes II and III, and not significantly altered 
with class IV drugs. The data suggest that amioda- 
rone and P-adrenoceptor blocking agents are the 
only drugs likely to reduce mortality while other 
agents may be ineffective or may actually increase 
the likelihood of a fatal arrhythmia. With the 
exception of the ESVEM trial mentioned earlier,24 
most of the major ongoing studies are with amioda- 
rone, with European and Canadian postmyocardial 
infarction trials, and 2 placebo-controlled trials in 
heart failure: the Veterans Affairs Congestive Heart 
Failure trial of antiarrhythmic therapy and the 
group study of heart failure survival in Argentina 
(GESICA). 
Pharmacologic protection: direct or indirect? 
Except where ancillary electrophysiologic proper- 
ties are part of a particular agent’s pharmacologic 
profile, the p-adrenergic receptor antagonists, as a 
group, appear to be devoid of a direct effect on the 
heart. Despite this, several studies have reported 
significant antiarrhythmic effects with these drugs, 
both in clinicaP and in experimenta187,88 studies. 
Our laboratory has examined several P-adrenocep- 
tor blocking agents for potential antiarrhythmic 
and antifibrillatory activity in the canine model of 
sudden cardiac death. Nadolol, a noncardioselec- 
tive agent, was studied in the sudden death proto- 
col after pretreatment with 1 (n = 9) and 8 (n = 13) 
mgikg. Respective survival figures were 56% and 
63% (p < 0.01 vs placebo).84 o-Nadolol, an optical 
isomer devoid of l3-adrenoceptor blocking proper- 
ties, was ineffective. An interesting feature in this 
study was the observation that the majority of 
nadolol-treated dogs that died, did so, not from 
ventricular fibrillation, but as the result of com- 
plete heart block, severe bradycardia, and/or pump 
failure. This phenomenon was also observed in 
subsequent studies with dilevalol, the R,R-enanti- 
omer of labetalol, where 75% of deaths were 
accompanied by severe bradyarrhythmias.54Jj” The 
administration of methylscopolamine to postinfarc- 
tion animals pretreated with dilevalol, however, 
significantly reduced mortality (40% vs 100% ve- 
hicle-treated; p < 0.05), suggesting that dilevalol, 
like nadolol, was capable of preventing ischemic 
ventricular fibrillation in this model, but that death 
was due to the unopposed effects of parasympa- 
thetic influences plus the inability of the sinoatrial 
node to manifest a positive chronotropic action 
due to the presence of l3-adrenoceptor inhibition. 
In a series of experiments with celiprolol, a class 
II drug with intrinsic stimulant properties, it was of 
significance that the drug was without effect in 
preventing sudden cardiac death.64 In particular, 
ventricular fibrillation was responsible for each of 
the 7 deaths in the drug-treated group. Although 
the model is not designed specifically to address 
the question of intrinsic cardiostimulant phenom- 
ena, it was noted that resting heart rate did not 
change after celiprolol administration, and it is 
possible that this feature of the drug attenuated 
any protection during acute posterolateral isch- 
emia. It has been demonstrated, for example, that 
the propensity of sympathetic stimulation to in- 
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duce arrhythmias in the late myocardial infarction 
period may relate primarily to heart rate.89 Previ- 
ous studies have shown antagonism of the antiar- 
rhythmic protection afforded by propranolol by 
overdrive atria1 pacing. 9o These studies also re- 
ported that P-adrenoceptor antagonists demon- 
strated an almost linear relation between the 
reduction in resting heart rate and mortality and 
noted that drugs with intrinsic sympathomimetic 
activity produced small reductions in heart rate 
and lesser effects on mortality.62 Although it is 
unclear whether celiprolol’s stimulant properties 
are due entirely to partial agonism,91 intrinsic 
sympathomimetic activity is cited as a possible 
reason why the drug failed to exert a beneficial 
influence on ventricular arrhythmias in a group of 
patients with acute myocardial infarction.92 
In an attempt to clarify the role of heart rate in 
the genesis of sudden death, we evaluated the 
antifibrillatory effects of alinidine, the N-ally1 de- 
rivative of clonidine. Alinidine is one of a number 
of agents in which the main pharmacologic action 
appears to be a reduction in heart rate from a 
direct action on the sinus node.93394 Although 
capable of attenuating the chronotropic response 
to isoproterenol, these drugs do not operate by 
antagonism of 13-adrenoceptors.93395 Similarly, there 
is no evidence that the specific bradycardic action 
involves a-adrenergic or muscarinic receptors, or 
calcium channels.93,95F96 However, studies in iso- 
lated tissues have shown a nonvoltage-dependent 
decrease in the slope of the slow diastolic depolar- 
ization, indicating that the drugs’ effects may be 
mediated by restriction of current through anion- 
selective channels.96 In the canine model of sudden 
cardiac death, alinidine (1 mg/kg) produced a 
significant (p < 0.01) decrease in resting heart rate 
and prevented ventricular fibrillation in 6 of 10 
animals studied (p <0.05 vs concurrent placebo 
group). In a third group of dogs in which constant 
atria1 pacing maintained heart rates at predrug 
values throughout the sudden death protocol, mor- 
tality was 100% despite pretreatment with alini- 
dine.65 No changes were observed on parameters of 
ventricular refractoriness or conduction velocity. 
Bradycardic agents, such as the P-adrenoceptor 
antagonists, are capable of increasing perfusion 
pressure distal to a coronary artery stenosis,97 an 
effect that, for the bradycardic agents at least, 
appears to be attenuated by atria1 pacing to control 
(predrug) heart rate values.98 Thus, during postero- 
lateral ischemia, drugs with a negative chrono- 
tropic action may contribute to an enhanced collat- 
eral flow in the ischemic bed secondary to slowing 
of heart rate, prolongation of diastole, and pre- 
sumed reduction in myocardial oxygen consump- 
tion. 
An additional property of the P-adrenoceptor 
antagonists is their ability to attenuate the poten- 
tially deleterious influence of enhanced adrenergic 
stimulation. In this respect, it is interesting to 
consider results in the sudden death model with 
the ai-adrenoceptor antagonist prazosin. Despite 
an inability to alter electrocardiographic intervals, 
ventricular refractoriness, or the induction of ven- 
tricular tachycardia by programmed stimulation, 
pretreatment with 500 kg/kg of prazosin resulted 
in a 50% survival rate in the sudden death protocol 
(p <0.05 vs placebo). ‘O This may be of particular 
significance in view of the recent suggestion that 
a-adrenergic responsiveness may be enhanced un- 
der conditions of myocardial ischemia99 and that 
this is correlated with an increase in a-adrenocep- 
tor concentrationlo Although the relative contri- 
butions of 01- and P-adrenergic influences in the 
genesis of ventricular fibrillation remain unclear, it 
has been suggested that a-mediated prolongation 
of action potential duration in ischemic areas may 
combine with P-mediated shortening of action 
potential duration in nonischemic areas to increase 
disparity in refractory periods and produce the 
arrhythmogenic milieu suitable for the emergence 
of fatal reentrant pathways.‘O’ Antagonism of ei- 
ther adrenergic pathway (by the respective adrener- 
gic antagonist) could therefore be seen as an 
indirect reduction in the electrophysiologic de- 
rangements leading to ventricular fibrillation and 
explain the protection afforded by both the P-adre- 
noceptor antagonists and prazosin in the animal 
model of sudden cardiac death. 
In identifying a common direct electrophysi- 
ologic characteristic for antifibrillatory efficacy in 
the experimental model of sudden cardiac death, it 
becomes apparent that the greatest overall protec- 
tion has been seen with agents that have as part of 
their pharmacologic profile prolongation of the 
action potential duration (class III activity). Stud- 
ies with bretylium,lo2 amiodarone,lo3 sotalol,lo4J05 
and a number of experimental agentsloGlo8 have 
demonstrated significant protection in placebo- 
controlled studies. The effects of clofilium, an 
alternative class III drug, were less clear-lo9 and 
may relate to a failure to provide an appropriate 
dosing regimen. 
Bretylium was introduced into clinical cardiol- 
ogy in the early 1980s and is currently one of the 
few drugs marketed as an antifibrillatory agent. Its 
electrophysiologic properties include direct effects 
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on cardiac action potential duration and indirect 
effects mediated via its actions on the autonomic 
nervous system. Early studies with the drug demon- 
strated suppression of stimulus-induced ventricu- 
lar tachycardiallOJ1l and elevation in ventricular 
fibrillation thresholds.lr2 In the sudden cardiac 
death model, bretylium (10 mg/kg intravenously 
every 6 hours) resulted in significant prolongation 
of ventricular refractoriness and the survival of 6 of 
the 10 animals studied (p <0.05 vs placebo). The 
exact antifibrillatory mechanism of the drug, how- 
ever, remains obscure; although bretylium has 
been shown to exert similar electrophysiologic 
effects in the denervated heart,‘13 the significance 
of its autonomic effects on the development of 
ventricular fibrillation is unknown. Further, studies 
with bethanidine6s and meobentine69 failed to pre- 
vent ventricular fibrillation and sudden death in 
the same model, despite similar structural and 
electrophysiologic characteristics. 
Amiodarone originally was introduced as an 
antianginal agent, but subsequently was found to 
have electrophysiologic features attributable to 
each of the 4 classes of antiarrhythmic action.114-116 
In addition, the drug reduces the inotropic and 
chronotropic responses of other agents and has 
vasodilatory effects on the coronary and systemic 
vasculature.117 Its outstanding property, however, 
is prolongation of the cardiac action potential, 
prompting its identification as a potential antifibril- 
latory agent. Despite the observation that alter- 
ations in action potential duration and ventricular 
refractoriness are apparent only with chronic dos- 
ing, studies in our laboratory have demonstrated 
significant antifibrillatory protection after both long- 
and short-term oral therapy. Although no differ- 
ences were observed in plasma or myocardial 
concentrations of amiodarone between the 2 dos- 
ing regimens, the greater survival in those animals 
treated for 10 days (80% vs 60% treated acutely) 
suggests that long-term therapy may have addi- 
tional, as yet unidentified actions contributing to 
greater efficacy. It is known that the electrophysi- 
ologic effects of amiodarone resemble closely those 
of hypothyroidism 118J19; that this is not due to the 
iodine moiety of the drug has been shown in 
experiments where the administration of iodine 
has had no effect on cardiac action potentials.120 
However, the concomitant administration of amio- 
darone and thyroid hormone has prevented the 
repolarization changes seen with amiodarone alone, 
and thyroidectomy can protect postinfarction ani- 
mals from ischemic ventricular fibrillation in the 
sudden death protocol.121 
The effects of sotalol and its dextrorotatory 
enantiomer, D-sotalol, have been of particular 
importance in correlating the antifibrillatory poten- 
tial of pharmacologic agents with their known 
electrophysiologic characteristics. Racemic sotalol 
is a noncardioselective P-adrenoceptor antagonist 
that produces a dose-dependent prolongation of 
action potential duration without associated class I 
(membrane-stabilizing) properties; D-sotalol, how- 
ever, while retaining the same cardiac electrophysi- 
ologic profile, does not share to the same extent the 
parent compound’s l3-adrenoceptor blocking prop- 
erties. The use of D-sotalol allows an assessment of 
the relative antifibrillatory action of the drug’s 
direct electrophysiologic effects, divorced from the 
confounding influence of l3-adrenoceptor antago- 
nism. Initial studies with racemic sotalol demon- 
strated a 65% survival in animals treated with the 
drug and entered into the sudden death proto- 
~01.‘~ The protective effect was associated with 
significant prolongation of the QT interval (an 
electrocardiographic parameter of action potential 
duration) and bridging diastolic electrical activity 
of the lead II electrocardiogram, a phenomenon 
invariably followed by ventricular fibrillation in 
vehicle-treated animals. In a subsequent study with 
the D isomer, Lynch and coworkerslOs demon- 
strated similar electrophysiologic and antifibrilla- 
tory effects, but without the attenuation of the 
ischemia-induced increase in heart rate seen with 
the parent compound. This suggested that the 
observed antifibrillatory effect of D-SOtdO was not 
related to antagonism of the P-adrenoceptor, but 
stemmed directly from prolongation of action po- 
tential duration and the increase in the ventricular 
refractory period. 
More recent studies from this laboratory have 
reinforced the positive trend seen with agents 
sharing the ability to prolong ventricular refractori- 
ness. The experimental agents CK-3579 and sema- 
tilide,lo6 E-4031,“” and UK-68,7981°8 have pro- 
duced protection in placebo-controlled studies in 
the canine model of sudden cardiac death. 
CLASS III ANllARRHYlHMIC AGENTS 
One actlvfty, but uncertain mechanisms: The 
Vaughan Williams classification was the first seri- 
ous effort to classify antiarrhythmic agents based 
on what was known regarding common electrophysi- 
ologic characteristics of the available drugs in the 
early 1970s. 122 It is widely recognized, however, 
that the classification is not without major inadequa- 
cies, not least of which being that the system is 
essentially a hybrid: Classes I and IV represent 
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agents that impair ion channels; class II agents 
inhibit receptors; and class III agents change an 
electrophysiologic variable (the action potential 
duration).123 Although actual mechanisms contrib- 
uting to the class III effect were not known 20 years 
ago, the common feature now appears to be inter- 
ruption of normal potassium efflux by antagonism 
of one or more of the potassium channels.124J25 
With the increased understanding of the role of 
various potassium channels in health and disease 
has come an explosion of publications on the 
subject and an ever-increasing number of newly 
discovered channels in various organ systems.126 
PDTASSIUM CURRENTS THAT PREDGMINATE 
DURING ALTERED METABDUC STATES 
Abnormalities of membrane function arise in 
response to myocardial ischemia or hypoxia and 
favor the development of slow conduction and 
unidirectional block. Both conditions are essential 
for establishing a reentrant pathway capable of 
supporting ventricular tachyarrhythmias. Among 
the electrophysiologic changes observed in the 
ischemic or hypoxic tissue is the abrupt increase in 
extracellular potassium concentration accompa- 
nied by intracellular acidosis and a decrease in 
tissue adenosine triphosphate concentration. Myo- 
cardial hypoxia is associated with K+ efflux from 
cardiac myocytes and a shortening of the action 
potential duration. 127~128 A mechanism involving 
opening of K+ selective channels during ischemia 
has been proposed to account for ischemia- 
induced myocyte K+ loss. In addition, conditions of 
metabolic inhibition, as with ischemia or hypoxia, 
lead to the liberation of free fatty acids and a gain 
in intracellular sodium and calcium ions. The 
decrease in tissue adenosine triphosphate content, 
the increase in tissue free fatty acids, and the gain 
in intracellular sodium and calcium ions, each 
activate separate potassium channels. The single- 
channel conductance of the K+ channels activated 
under pathophysiologic conditions is greater than 
that occurring when K+ channels are operative 
under normal conditions. Conditions of altered 
myocardial metabolism resulting from hypoxia 
and/or ischemia would favor outward rectification, 
so that the outward current predominates over the 
inward current. Significant outward current would 
flow during depolarization, resulting in a decrease 
in the action potential duration. The accumulation 
of K+ in the extracellular space will depolarize the 
myocardial cell membrane. The net result of the 
local ionic events is to decrease conduction velocity 
and shorten the effective refractory period, which 
in the presence of a suitable myocardial substrate 
has the potential to result in a lethal arrhythmia. 
The 3 K+ channels that predominate under patho- 
physiologic conditions may act synergistically to 
favor outward rectification and provide the condi- 
tions needed for reentry. The most widely studied 
of the 3 pathophysiologic channels in the heart is 
the adenosine triphosphate-dependent potassium 
channel (KATp). 
With the discovery of a KATP channel regulating 
insulin release in the pancreatic islet l3 ce11s,129 and 
its subsequent determination in the heart,130 came 
the realization of a cardiac channel active only in 
pathologic (hypoxic or ischemic) circumstances, 
where it could potentially play a crucial role in the 
genesis of fatal reentrant arrhythmias. Further, the 
functional or active KArp channels would become 
manifest only in myocardial cells in which intracel- 
lular adenosine triphosphate was decreased. The 
concept was supported by the finding that gly- 
buride, a sulfonylurea that (like all members of its 
class) exerted an antidiabetic effect by promoting 
the closure of pancreatic KATP channels, could also 
reverse the electrophysiologic consequences of isch- 
emia in isolated myocardial cells.131 At about the 
same time, independent research had demon- 
strated that glyburide was effective in preventing 
the development of ventricular fibrillation in iso- 
lated heart preparations under conditions of low 
intracellular adenosine triphosphate, whether the 
result of ischemia132J33 or hypoxia.134 When hearts 
are made hypoxic or ischemic in the presence of 
glyburide, the potassium loss during the early 
phase is partially blocked by the glyburide.135-137 
Based on these observations, it appears that part of 
the potassium loss during hypoxia or ischemia can 
be attributed to activation of the KATP channel, 
although other mechanisms may be involved, such 
as the Na+-activated and fatty acid sensitive K+ 
channels. Thus, arachidonic acid and its metabo- 
lites, as well as other unsaturated fatty acids, can 
modulate K+ channel activity. Understanding the 
manner in which pharmacologic interventions 
modulate the several potassium channels in the 
ventricular myocardium is complicated by the fact 
that there seems to be an interaction among the 
activity of potassium-channel modulators and tis- 
sue metabolites. For example, the effectiveness of 
glyburide to block the KATP channel depends on 
the cytosolic concentration of adenosine diphos- 
phate,138 whereas the ability of pinacidil to act as 
an opener depends on the cytosolic content of 
adenosine triphosphate. 139~140 There is no doubt 
that the tissue content of both adenosine triphos- 
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phate and adenosine diphosphate will be altered 
during intervals of hypoxia and ischemia as well as 
on reperfusion. Thus, alterations in tissue metabo- 
lites will influence the final outcome of any experi- 
mental protocol and may account for incongruous 
results among laboratories, because the content of 
tissue metabolites may vary according to the particu- 
lar experimental protocol employed. 
Our laboratory has confirmed the antifibrilla- 
tory effect glyburide in the rabbit isolated heart 
made hypoxic in the presence of pinacidili4’ (Fig- 
ure 3). Pinacidil promotes intracellular potassium 
efflux and significantly reduces action potential 
duration via an agonist effect on KATr chan- 
ne1s.1”9J42 In the normoxic heart under atria1 pac- 
ing, pinacidil is without discernible effects on 
cardiac rhythm, despite the fact that a significant 
decrease in ventricular effective refractory period 
occurs, presumably due to opening of the KArp 
channel. However, in the presence of pinacidil, but 
less likely in its absence, ventricular fibrillation 
occurs in >80% of hearts made hypoxic for 12 
minutes or occurs shortly after the heart is reoxygen- 
ated.141 The induction of ventricular fibrillation in 
the presence of pinacidil is dependent on a de- 
crease in myocardial cell adenosine triphosphate 
content (Figures 4 and 5), thereby suggesting that 
the myocardial K *rP channel shows increased re- 
sponsiveness to the agonist effects of pinacidil 
when it is disinhibited as a result of decreased 
cellular adenosine triphosphate. Glyburide, known 
for its ability to inhibit the KArp channel, prevents 
the pinacidil-induced decrease in the effective 
refractory period and significantly reduces the 
incidence of ventricular fibrillation in the hypoxic/ 
reoxygenated perfused heart.14i The profibrillatory 
action of pinacidil is unmasked by myocardial 
hypoxia or ischemia, either of which will decrease 
myocardial cell adenosine triphosphate content. It 
is anticipated that a lowering of myocardial adeno- 
sine triphosphate will favor opening of the K~rp 
channel, especially in the presence of the agonist 
pinacidil. The 2 events, lowering of cellular adeno- 
sine triphosphate and further opening of the KATP 
channel by the agonist pinacidil, would favor the 
rapid outward movement of potassium and a 
marked decrease in the ventricular refractory pe- 
riod. 
It is proposed that a special binding site is 
located on the intracellular side of the membrane 
by which adenosine triphosphate closes the KArp 
channel.14” Opening of the KArp channel occurs 
when intracellular adenosine triphosphate content 
is reduced. Under conditions of reduced intracellu- 
lar adenosine triphosphate, pinacidil is more likely 
to facilitate an opening of the KArp channel, 
thereby enhancing an effect similar to that of a 
reduced intracellular adenosine triphosphate con- 
centration. It has been suggested that pinacidil 
opens the KArp channel by antagonizing adenosine 
triphosphate binding or that pinacidil binds to a 
different site and modulates the affinity of the 
receptor to adenosine triphosphate by a pseudo- 
competitive action. 144 Consistent with this explana- 
tion is the observation that only channels closed by 
low concentrations of adenosine triphosphate could 
be opened by potassium channel agonists.139J45 
Therefore, the “open” probability of the KATZ 
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channel can be significant in the absence of adeno- 
sine triphosphate and can be influenced further by 
the interaction of cofactors formed during isch- 
emia or hypoxia, as discussed above. 
The possibility must be entertained that during 
ischemia there may be a finite probability for the 
channel to open. Half-maximal sensitivity of the 
channel increases 4-fold by the addition of adeno- 
sine diphosphate and guanosine diphosphate in 
concentrations known to exist during metabolic 
inhibition or ischemia.146J47 A significant open 
probability of the KArP channel may be expected 
under appropriate conditions, even with millimolar 
concentrations of adenosine triphosphate.147J48 The 
KATP channel-dependent action potential shorten- 
ing is likely to occur if adenosine triphosphate 
concentration falls below normal levels (approxi- 




RGURE 4. Representative recordlrgfrom the rabbR lso- 
kited heart during nonaoxk and hypoxk perfusion. The 
tfaclagsfromabovedcwmvardrepresenkoxygei~tenslon 
of the perfwlon medum, left veabtcular kdP/dt, coronary 
perfush pressure, and left ventricular developed pres- 
sure. The Rmctlonal effects of changing the gas mixture In 
the artifklal lung be4come evident wRhln 1 minute as mani- 
fested by a decrease In kdP/dt, coronary artery perfusion 
pressum and left ventrkular developed pressure. Myc- 
cardlal tlssue content of adeaoslae trlphosphate ls re- 
duced approximately 50% during the l2-minute exposure 
to hypoxk perblon. 
mately 5 rnM), as may happen regionally or glo- 
bally during myocardial ischemia.149 The known 
relation between cellular adenosine triphosphate 
concentration and the functioning of the KArP 
channel would suggest that selective channel ago- 
nists should be more effective in the ischemic heart 
than in normal myocardium. Our observations in 
the intact postinfarcted canine heart and in the 
hypoxic perfused heart would support the conclu- 
sion that KArp channel openers, while of no delete- 
rious consequence during normal oxygenation, be- 
come profibrillatory under conditions of metabolic 
inhibition leading to a decrease in intracellular 
adenosine triphosphate concentration.133J41J50J51 
Confusion arises over whether it is more advan- 
tageous to restore an abnormally shortened action 
potential to a normal action potential by applica- 
tion of a KATP channel closer (e.g., glyburide) or to 
shorten further the action potential in cardiac cells 
by administration of a KArP channel opener (e.g., 
pinacidil). Studies designed to examine myocardial 
recovery of contractile function suggest the latter 
alternative as the more desirable course of action 
to prevent the deleterious effects of ischemia and 
preserve the viability of cardiac cells and recovery 
of contractile function.152-156 Future studies must 
address the issue of whether it is more important to 
preserve contractile function at the risk of jeopar- 
dizing electrophysiologic properties of the heart 
subjected to metabolic inhibition. Will inhibitors of 
the K~rp channel, other than glyburide, have the 
same undesirable effects on recovery of function? 
To date, class III antiarrhythmic agents known to 
inhibit the delayed rectifier current have not been 
Control Hypoxia 
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shown to influence ischemic myocardial injury157 
but in contrast may exhibit a positive inotropic 
action as assessed by the measurement of dPldt. 158 
The class III antiarrhythmic agents differ signifi- 
cantly from glyburide with respect to modulating 
the effects of ischemia on myocardial tissue, since 
the latter has been reported to have a negative 
influence on functional recovery and tissue viability 
after ischemic myocardial injury.152J59 
Pharmacologic interventions directed at block- 
ing the KATP channel, thereby preventing a de- 
crease in the ventricular refractory period, may 
provide a useful approach to the prevention of 
ventricular fibrillation, without necessarily possess- 
ing antifibrillatory activity as manifested by the 
reduction or prevention in premature ventricular 
depolarizations. Based on these observations, it is 
suggested that inhibition of the Kerr channel, by 
preventing potassium efflux, will antagonize reduc- 
tions in the action potential duration and will 
prevent the shortening of refractoriness in isch- 
emit and adenosine triphosphate-depleted myocar- 
dial cells. By so doing, disparity in refractory 
periods can be avoided and with it the risk of 
emergent ventricular reentrant arrhythmias. 
Using a cohort of small-infarct, noninducible 
dogs similar to those described above in the flecain- 
ide study, we evaluated the profibrillatory action of 
pinacidil in the sudden cardiac death model. Com- 
pared with a 24-hour mortality in the placebo 
group of 20% (incidence of ischemic ventricular 
fibrillation, 6.7%) mortality in the pinacidil group 
was 87% (ischemic fibrillation, 60%), a difference 
statistically significant at the p < 0.01 level. Changes 
in arterial blood pressure did not reach statistical 
significance, indicating that the profibrillatory ef- 
fect could not be explained on the basis of hypoten- 
sion.150 These studies provide further support for 
the pivotal role of the KATp channel in the genesis 
of fatal cardiac arrhythmias. In the search for the 
KATP channel antagonist to be developed as the 
first potential antifibrillatory agent, the hypoglyce- 
mic properties of the sulfonylureas make their 
evaluation particularly difficult in the intact ani- 
mal. However, a number of unrelated compounds 
claim to have KATP-blocking activity as part of their 
pharmacologic profile; one in particular, 5-hy- 
droxydecanoic acid, purports to be a “pure” K*rp 
channel antagonist and appears to attenuate isch- 
emit ventricular fibrillation in the rat heart.160 The 
preliminary results with 5-hydroxydecanoic acid 
require further evaluation in appropriate in vivo 
models. 
Most of our understanding of the channel block- 
ing actions of class III antiarrhythmic agents is 
derived from voltage clamp studies. Such studies 
provide a clear demonstration of an hypoxia- 
induced increase in time-independent K+ current 
as being the important factor in shortening of the 
ventricular action potential. Although the derived 
information is promising, there remains a void in 
our knowledge concerning the relation of the 
observed electrophysiologic and ionic changes to 
the onset of malignant disturbances in cardiac 
rhythm under conditions that approximate the 
clinical situation of sudden cardiac death. The use 
of the canine model of sudden cardiac death has 
proved valuable in bridging the gap between the 
electrophysiologic studies and events as they occur 
in the intact heart under pathophysiologic condi- 
tions. The isolated perfused rabbit heart subjected 
to hypoxia and tested with the Kerr channel 
opener, pinacidil, represents a valuable addition to 
the study of class III antifibrillatory agents. In this 
model, the induction of ventricular fibrillation is 
dependent on the hypoxia-induced decrease in 
tissue adenosine triphosphate content together 
with the influence of the KArp channel opener 
pinacidil to facilitate the opening of the KATP 
channel. The ability of glyburide and a number of 
class III antiarrhythmic agents (E-4031, 5-hy- 
droxydecanoate) to protect against the develop- 
ment of ventricular fibrillation suggests a role for 
the KArp channel in the development of ventricular 
fibrillation (Figure 6). The antifibrillatory action of 
these agents may be attributed, in part, to the 
suppression of K+ release from hypoxic or ischemic 
myocardium, perhaps through inhibition of the 
adenosine triphosphate-regulated K+ channel. We 
believe that it is the tissue adenosine triphosphate 
content and not the direct effects of hypoxia or 
reoxygenation that influences the action of pinaci- 
dil on cardiac rhythm. The K+ channel putatively 
responsible for ischemia or hypoxia-induced K+ 
loss is the adenosine triphosphate-dependent K+ 
channel present in cardiac cells.130 Under normoxic 
conditions, the adenosine triphosphate-dependent 
K+ channel is blocked by high intracellular adeno- 
sine triphosphate concentrations. Depletion of cel- 
lular adenosine triphosphate (as can occur during 
hypoxia, ischemia, or in the presence of a meta- 
bolic inhibitor) disinhibits the blockade of the 
channel and allows for K+ efflux to occur. A role 
for the adenosine triphosphate-dependent K+ chan- 
nel in hypoxia/ischemia-induced K+ loss has been 
shown by specific inhibition with glyburide or 
tolbutamide.133J35J61 Glyburide inhibits both isch- 
emia-induced myocardial K+ loss and ischemia- 
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induced ventricular fibrillation. The latter observa- 
tion provides evidence that the K+ loss resulted 
from opening of the adenosine triphosphate- 
dependent K+ channel and that the K+ efflux was 
related to the onset of ventricular fibrillation.135 
The results of our studies may be interpreted as 
suggesting that pharmacologic opening of the aden- 
osine triphosphate-dependent K+ channel during 
hypoxia (decrease in myocardial adenosine triphos- 
phate) or on reoxygenation (sustained decrease in 
myocardial adenosine triphosphate content) makes 
the myocardium more susceptible to the develop- 
ment of ventricular fibrillation. The suggestion that 
under certain conditions K+ channel agonists may 
facilitate the development of ventricular fibrilla- 
tion concurs with in vivo data showing the profibril- 
latory action of pinacidil under conditions of re- 
gional myocardial ischemia in the presence of a 
previous myocardial infarction.150 
In addition to demonstrating antifibrillatory ac- 
tivity for specific interventions, results obtained in 
the isolated heart have supported the observations 
in the intact animal in which profibrillatory events 
have been uncovered, as was the case with flecain- 
ide.73J62 Class I antiarrhythmic agents (quinidine, 
aprindine, lidocaine, and flecainide) were selected 
for study in the isolated heart made hypoxic and 
treated with pinacidil. Only quinidine prevented 
the pinacidil-induced ventricular fibrillation. Fle- 
cainide in the presence of hypoxia, but in the 
absence of pinacidil, invariably was associated with 
the onset of ventricular fibrillation that could be 
prevented by pretreatment with glyburide.162 The 
observations suggest that ventricular fibrillation 
can be provoked by the potassium channel agonist 
pinacidil or by flecainide, under conditions that 
reduce intracellular adenosine triphosphate concen- 
tration. Glyburide, a selective antagonist of the 
KATP channel, prevented the profibrillatory actions 
of both pinacidil and flecainide. 
CONCLUSION 
The lack of effective and safe drugs for the 
prevention of lethal arrhythmias and sudden car- 
diac death has served to stimulate renewed interest 
in the area of drug development and the introduc- 
tion of several new candidate agents that share a 
common ability to prolong ventricular refractori- 
ness. Equally important is the recognition that 
most antiarrhythmic agents have been evaluated 
with in vitro or in vivo models that have little 
relevance to the clinical situation of sudden cardiac 
death. As the recent CAST reporti7J8 has empha- 
sized, the final analysis of a drug’s ultimate utility 
will depend on appropriate clinical testing in pa- 
tients who are at risk of developing sudden and 
unexpected life-threatening arrhythmias, or ven- 
tricular fibrillation, or both. 
We can no longer afford to employ the more 
expedient and less dependable approach to evalu- 
ating new agents for their ability to reduce the 
frequency and/or complexity of ventricular depolar- 
izations or their ability to modify the patient’s 
response to programmed electrical stimulation. 
Despite the formidable task involved in the clinical 
assessment of an effective therapy for the preven- 
tion of ventricular fibrillation, the challenge could 
be made more readily attainable by preclinical 
assessment of a candidate drug, based on studies 
conducted in relevant animal models using mean- 
r- 
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